May 24, 2018 10:03 PM ET

Healthcare Equipment and Supplies

Company Overview of Access Bio, Inc.

Company Overview

Access Bio, Inc. researches, develops, manufactures, and sells in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company has a strategic partnership with Atomo Diagnostics. Access Bio, Inc. was founded in 2001 and is headquartered in Somerset, New Jersey.

65 Clyde Road

Suite A

Somerset, NJ 08873

United States

Founded in 2001

Phone:

732-873-4040

Key Executives for Access Bio, Inc.

Access Bio, Inc. does not have any Key Executives recorded.

Access Bio, Inc. Key Developments

Access Bio, Inc. - Special Call

To discuss the business status explanation and forecast

Atomo Diagnostics and Access Bio Inc. Partners to Expand Access to Best-In-Class Hiv Rapid Testing in Global Markets

Atomo Diagnostics and Access Bio Inc. announce a strategic partnership to leverage the respective strengths of both innovative rapid diagnostic test (RDT) companies to expand point of care HIV testing in global markets. The partnership will see Atomo supply its award-winning AtomoRapid™ lateral flow diagnostic test platforms for use with Access Bio’s in vitro HIV rapid test that detects the presence or absence of HIV antibodies in a single drop of blood obtained from a fingertip. The test result can be read in minutes, which is essential for same day diagnosis and early treatment and care. The new test product will be commercialised by Access Bio in professional use markets under its CareStart™ brand in territories across Africa, South East Asia, South America and CIS countries. In September 2016, the World Health Organisation (WHO) forecast that demand for HIV rapid diagnostic tests in the territory will increase by one third, to reach more than 400 million tests per year by 2020. Dedicated to the prevention and early diagnosis of infectious diseases, Access Bio and its subsidiary, Wells Bio Inc., manufacture more than 120 million rapid diagnostic tests annually for the detection of a range of infectious diseases, including malaria, dengue and HIV. The new partnership with Atomo Diagnostics will strengthen its rapid test portfolio and support continued growth.

Access Bio, Inc.(KOSDAQ:A950130) dropped from S&P Global BMI Index

Access Bio, Inc.(KOSDAQ:A950130) dropped from S&P Global BMI Index

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
206 Ortho, Inc. United States
21st Century Scientific, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Access Bio, Inc., please visit www.accessbio.net. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.